Date: 2026-04-06 Quarter: Q4 FY2025 (Dec 2025) — First public earnings call (IPO Jan 28, 2026) Market cap: ~$748M | Price: 11.89|Shares : 62.9MEV: 430M (net cash ~$318M incl. IPO proceeds) | EV/TTM Rev: 1.1x
I haven't written about LIFE specifically — this is my first look. So rather than formal prior beliefs, let me state what I was looking for walking in:
| | Q424 | Q125 | Q225 | Q325 | Q425 | | | Dec-24 | Mar-25 | Jun-25 | Sep-25 | Dec-25 | |---|---|---|---|---|---| | Revenue ($M) | 66.5 | ~89.0 | ~94.0 | ~95.0 | **110.1** | | YoY % | +66% | +58% | +34% | +53% | **+65.5%** | | QoQ % | — | +33.8% | +5.6% | +1.1% | **+15.9%** | | Gross Margin % [GAAP] | 97.7% | ~98% | ~98% | ~98% | **98.1%** | | Op Margin % [GAAP] | 18.8% | — | — | — | **22.2%** | | Net Margin % [GAAP] | 14.3% | — | — | — | **22.3%** | | Adj EBITDA ($M) | ~15 | ~19 | ~21 | ~24 | 25.8 | | EBITDA Margin % | ~22% | ~21% | ~22% | ~25% | 23% | | Policies Activated | 38,515 | 46,283 | 49,219 | 48,122 | 54,714 | | ARPU ($) | 1,727 | 1,920 | 1,906 | 1,972 | **2,012** | | Contribution Margin % | 39.1% | 41.6% | 40.4% | 42.1% | **42.9%** | | Direct Rev ($M) | ~38 | ~50 | ~56 | ~62 | 74.2 | | 3P Rev ($M) | ~28 | ~33 | ~38 | ~38 | 35.9 |
Q1-Q3 FY25 revenue/EBITDA approximate from investor presentation charts. Full P&L only for Q4 FY24 and Q4 FY25.
Annual:
| Year | Revenue ($M) | YoY % | EBITDA ($M) | EBITDA Mgn | Net Income ($M) | Net Mgn | OCF ($M) |
|---|---|---|---|---|---|---|---|
| FY2023 | 159.8 | — | ~7 | ~4% | — | — | — |
| FY2024 | 254.9 | +59.6% | 58.0 | 22.8% | 48.8 | 19.2% | (10.9) |
| FY2025 | 387.6 | +52.1% | 89.0 | 23.0% | 71.2 | 18.4% | 36.2 |
Three consecutive years above 50% is not common. What's more telling is the quarterly pattern: Q2-Q3 showed a concerning mid-year trough (+5.6% and +1.1% QoQ), but Q4 snapped back with +15.9% sequential growth and +65.5% YoY — the highest annual exit rate. Revenue re-accelerated. That's not what you see in a business running out of steam.
The Q1 2026 guide of $144-146M implies +53-63% YoY growth continuing into the new year. If they hit that, the annual run rate is $580M+. The FY2026 guide of $512M (+32%) is almost certainly conservative — this is their first public guidance ever, and the Q1 number alone annualizes well above the full-year guide. Shows what I know, but I'd bet on them beating FY2026 handily.
98.1% gross margin. Let me say that again — ninety-eight percent. This is because Ethos is a distributor and administrator, not a risk-bearing carrier. The carriers hold 100% of balance sheet risk. Ethos collects commissions. This is closer to a software marketplace model than a traditional insurance business.
The operating margin expanded from 18.8% to 22.2% YoY (GAAP). Net margin went from 14.3% to 22.3%. This is a GAAP-profitable, 50%+ grower with improving margins. The Rule of 40 at 88 is exceptional — that puts it in the top tier of any growth company I've tracked.
Contribution margin (gross profit minus S&M, their key metric) expanded from 39.1% to 42.9% over five quarters. ARPU rose from $1,727 to $2,012 (+16.5%). Both moving in the right direction.
The ARPU expansion matters because it comes from product mix. New higher-value products (IUL, cancer insurance from Aflac) carry higher commissions per policy. This is a lever that can keep growing as they add VUL, annuities, and supplemental health to the platform.
At $11.89, LIFE trades at:
For a 50%+ grower with 98% gross margins, 22% GAAP operating margins, and $157M in cash. This is, to use a technical term, absurdly cheap.
The reason isn't the business — it's the post-IPO technicals:
In other words, the numbers match the theory just fine. The stock is cheap because of who's selling (nobody — locked up) and who might sell (everybody — after lockup). That's a technical dislocation, not a fundamental one.
This is where I have to be honest about what I don't know. One public quarter. No transcript available. I can't assess Q&A quality, management deflections, or how Peter Colis (CEO) and Chris Capozzi (CFO) handle tough questions. The CEO's prepared quote is standard fare — "exceptional topline growth" and "significant earnings potential." Shows confidence but tells me nothing I didn't already know from the numbers.
The guidance is specific and narrow-banded ($144-146M for Q1, $510-514M for FY), which I prefer to vague directional language. But I need to see them hit it before I assign credibility.
1. Direct vs. third-party channel divergence is the lead indicator to watch.
Direct channel revenue: +93% YoY in Q4, +19.7% QoQ. Accelerating. Third-party channel: +27% YoY, -5.5% QoQ. Decelerating and now declining sequentially.
Atlas flagged this and I agree it's the most important sub-metric. The direct channel is the agent platform business where Ethos controls the relationship. Third-party is carrier partnerships where Ethos has less leverage. If third-party continues declining, it could signal carriers pulling back or negotiating tougher terms. The offset is that the direct channel is large enough ($74M vs $36M) to carry growth on its own — but it requires more S&M spend.
2. Carrier concentration is the real fundamental risk.
Only 6 carriers, and the top 3 are estimated to represent 88-98% of revenue. Ethos is #1 source of premiums for 3 of them, which cuts both ways — it means they're deeply embedded, but it also means a single carrier departure would be catastrophic. I want to see this number move from 6 to 8-10 carriers over the next year.
3. The OCF inflection is underappreciated.
From negative $10.9M in FY2024 to positive 36.2MinFY2025.Thebusinessmodelgeneratescommissionsreceivablethatsitonthebalancesheet(253M total) — these are future cash flows from in-force policies. The gap between net income (71M)andOCF(36M) reflects working capital build, not operating inefficiency. As the book matures, OCF should converge toward net income. Asset-light + growing book of trail commissions = a business that should generate substantial free cash flow at scale.
4. The product expansion roadmap is credible.
From Term Life (FY2019) to Whole Life, IUL, Wills, Accidental Death, and Cancer Insurance (FY2025). Each new product increases ARPU and TAM. The jump from $12.6B addressable (existing products) to $140B+ (with annuities) is substantial. Management signaled VUL, Participating Whole Life, Annuities & Wealth Management, and Supplemental Health on the roadmap. I can't time these, but the pattern of one or two additions per year has been consistent.
5. No transcript = material analytical gap.
I can't assess management quality from a press release quote and a slide deck. The May 6, 2026 Q1 earnings call will be the first real test. I need to hear how they handle questions about carrier concentration, the third-party channel decline, the FY2026 deceleration guidance, and SBC ($10.6M FY25 — already 2.7% of revenue, will likely increase post-IPO).
Atlas scored this 4/5 conviction and called it "the cheapest high-quality growth company in the current market." I don't disagree with the math. But:
I'd weight the one-quarter track record more heavily. Atlas acknowledges it but doesn't let it limit the conviction score enough. One public quarter is one public quarter. I've seen too many IPOs deliver a strong debut quarter and then disappoint. The numbers are great; the sample size is one.
The FY2026 guide deserves more scrutiny. Atlas calls it "likely conservative first-year guide." Maybe. But the implied math (Q1 at $145M, remaining quarters averaging $122M) would mean sequential declines after Q1. That's unusual even for conservative guidance. I'd like to understand whether Q1 benefits from a seasonal pattern or whether the FY guide actually embeds real deceleration in H2.
Cash position matters for Bear specifically. I'm retired with no income stream. The lockup overhang means this stock could go lower before it goes higher. Even if I'm right about the business, I could be early on the stock. Sizing matters.
| Metric | Current ($11.89) | At $15 | At $19 (IPO) | Assessment |
|---|---|---|---|---|
| EV/TTM Rev | 1.1x | 1.7x | 2.3x | Cheap at all levels |
| P/E (TTM) | 10.5x | 13.3x | 16.8x | PEG 0.20 at current |
| EV/NTM Rev | 0.84x | 1.3x | 1.8x | Below 1x is remarkable |
| EV/EBITDA | 4.8x | 7.0x | 9.6x | Sub-5x for 50%+ growth |
| Rule of 40 | 88 | 88 | 88 | Top-tier |
At $11.89, this stock would have to triple to reach 3.3x EV/NTM revenue — a multiple that would still be cheap for a 30%+ grower. The valuation floor is solid. The question is timing, not value.
| Period | Revenue ($M) | Implied |
|---|---|---|
| Q1'26 guide (mid) | 145.0 | +53% YoY vs Q1'25 ~$89M |
| FY'26 guide (mid) | 512.0 | +32% YoY |
| Implied Q2-Q4'26 | 367.0 | Avg $122.3M/Q |
| Q4'25 actual | 110.1 | Baseline |
If Q1 comes in at $145M and management maintains FY guide, the implied back-three-quarters average of $122M/Q vs a $145M Q1 looks odd. Either:
I lean toward conservative sandbagging, but I want evidence before I bank on it.
Thesis: Intact (New Coverage)
Ethos is a high-quality, GAAP-profitable growth business with a structural valuation dislocation driven by post-IPO technicals. The platform model (98% gross margins, zero balance sheet risk, three-sided network effects) is the right model in a $140B+ market that's still 100 years old. At 1.1x EV/revenue, the market is giving me the business at a price that makes a lot of things forgivable.
But I don't invest based on hope. One quarter is one quarter. The carrier concentration risk is real and structural. The lockup creates a known catalyst window of uncertainty. I need to see Q1 delivery against guidance before I build real conviction.
Conviction: 3/5 — High-quality business at an attractive price, but conviction must be earned over time. One public quarter, no transcript, carrier concentration, and lockup overhang limit me from going higher.
Start a 2% position. The valuation provides a meaningful margin of safety. Even if the business decelerates to 30% growth (the FY26 guide), the stock is cheap. The risk/reward at 1.1x EV/revenue is asymmetrically favorable.
But I'm not going to let enthusiasm get ahead of conviction. Two percent and build from there. If Q1 beats (May 6), I'll add. If they miss their first public guidance, I'll reassess immediately.
Cash allocation: I'd fund this from my typical 10-30% cash reserve. At 2%, it's a starter position that won't keep me up at night even if the lockup drives it lower.
Key triggers for adding:
Key triggers for trimming/selling:
Bear